• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Acute Lung Injury - Pipeline Review, H2 2013 - Product Image

Acute Lung Injury - Pipeline Review, H2 2013

  • ID: 2708602
  • November 2013
  • 99 Pages
  • Global Markets Direct

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Mayo Clinic
  • Mondobiotech Holding AG
  • Polyphor Ltd.
  • Silence Therapeutics plc.
  • MORE

'Acute Lung Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury. Acute Lung Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Lung Injury.
- A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various READ MORE >

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Mayo Clinic
  • Mondobiotech Holding AG
  • Polyphor Ltd.
  • Silence Therapeutics plc.
  • MORE

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction

REPORT COVERAGE
Acute Lung Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Lung Injury
Acute Lung Injury Therapeutics under Development by Companies
Acute Lung Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acute Lung Injury Therapeutics - Products under Development by Companies
Acute Lung Injury Therapeutics - Products under Investigation by Universities/Institutes

Companies Involved in Acute Lung Injury Therapeutics Development
GlaxoSmithKline plc
Quark Pharmaceuticals, Inc.
Discovery Laboratories, Inc.
Silence Therapeutics plc.
Altor BioScience Corporation
Mondobiotech Holding AG
Polyphor Ltd.
Implicit Bioscience Limited
KYORIN Pharmaceutical Co., Ltd.
Techpool Bio-Pharma Co., LTD.
Mayo Clinic
Faron Pharmaceuticals, Ltd.
APEPTICO Forschung und Entwicklung GmbH
Acute Lung Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
POL-6014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dilmapimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lucinactant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-836 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Respiratory And Inflammatory Diseases Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRP-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atu-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rosuvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atu-134 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PanCyte - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-1995057 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT-2009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DasKloster-1000-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DasKloster-014101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
isoflurane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-0901317 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug Targeting Leptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stromal Cell Therapy For Acute Lung Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xib-1301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug Targeting Urokinase Plasminogen Activator - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug Inhibiting IGF-1R - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAT-SNAP-23 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rPAI-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1226 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1229 - Drug Profile
Product Description
Mechanism of Action

R&D Progress
Acute Lung Injury Therapeutics - Drug Profile Updates
Acute Lung Injury Therapeutics - Discontinued Products
Acute Lung Injury Therapeutics - Dormant Products
Acute Lung Injury - Product Development Milestones
Featured News & Press Releases
Oct 08, 2013: Discovery Labs Announces Notice of Allowance for a U.S. Patent Supporting the AEROSURF Development Program
Sep 09, 2013: New data from the ALI/ARDS FPCLI001 study presented at the 2013 European Respiratory Society meeting
Nov 01, 2012: Faron Pharma Receives €375,000 Grant From Tekes For Traumakine Program
Sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And US Government Agencies To Assess KL(4) Surfactant Utility In Acute Lung Injury
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics
May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting
Jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For CT-2009 Supporting Development In Acute Lung Injury
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients
Nov 08, 2011: Silence Provides Development Update Of Atu134
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Lung Injury, H2 2013
Products under Development for Acute Lung Injury - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
GlaxoSmithKline plc, H2 2013
Quark Pharmaceuticals, Inc., H2 2013
Discovery Laboratories, Inc., H2 2013
Silence Therapeutics plc., H2 2013
Altor BioScience Corporation, H2 2013
Mondobiotech Holding AG, H2 2013
Polyphor Ltd., H2 2013
Implicit Bioscience Limited, H2 2013
KYORIN Pharmaceutical Co., Ltd., H2 2013
Techpool Bio-Pharma Co., LTD., H2 2013
Mayo Clinic, H2 2013
Faron Pharmaceuticals, Ltd., H2 2013
APEPTICO Forschung und Entwicklung GmbH, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Acute Lung Injury Therapeutics - Drug Profile Updates
Acute Lung Injury Therapeutics - Discontinued Products
Acute Lung Injury Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Acute Lung Injury, H2 2013
Products under Development for Acute Lung Injury - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 39

GlaxoSmithKline plc
Quark Pharmaceuticals, Inc.
Discovery Laboratories, Inc.
Silence Therapeutics plc.
Altor BioScience Corporation
Mondobiotech Holding AG
Polyphor Ltd.
Implicit Bioscience Limited
KYORIN Pharmaceutical Co., Ltd.
Techpool Bio-Pharma Co., LTD.
Mayo Clinic
Faron Pharmaceuticals, Ltd.
APEPTICO Forschung und Entwicklung GmbH

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos